BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

NCT04673955 · clinicaltrials.gov ↗

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Carcinoma

Interventions

DRUG: Encorafenib
DRUG: Cetuximab

Sponsor

Pierre Fabre Pharma GmbH

Collaborators

[object Object]
[object Object]
[object Object]